Valion Bio has started a government-funded study to test Entolimod™ for preserving gastrointestinal tissue in partial-body acute radiation syndrome, a condition with no current effective treatments. The $7 million NIAID-backed study uses an FDA-accepted protocol and aims to support a Biologics License Application under the FDA's Animal Rule. Success would make Entolimod™ the only countermeasure protecting both hematopoietic and gastrointestinal tissues, addressing a critical gap in radiation injury treatment. The program is fully funded and supported by the U.S. government, reducing financial and regulatory risks for Valion Bio.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
